bioRxiv Science⌕ Search

Biology subjects

Aghabashlou Saisan, S.

Publications and source records attributed to Aghabashlou Saisan, S..

2 recordsLinked to original sources

Local consequences of FMRP loss: cell type-specific mRNA and protein profiles of Fmr1-KO synapses

Brain function relies on billions of neurons interconnected by synapses with unique molecular composition specialized for cell type, brain region, and their role in circuit dynamics. Pathological synaptic dysfunctions - so-called synaptopathies - underlie many neurodevelopmental disorders (NDDs), including Fragile X Syndrome (FXS). While synaptic deficits are well documented in FXS, molecular studies have largely relied on bulk brain homogenates or synaptic fractions, which typically represent ''average'' molecular identities, potentially masking synapse type-specific alterations. To provide synapse type resolution, we use fluorescence-activated synaptosome sorting coupled to RNA-sequencing and mass spectrometry to isolate and profile cortical excitatory and inhibitory synapses of hemizygous and heterozygous Fmr1-deficient mice. We found that full or partial FMRP loss leads to cell type- and compartment-specific molecular remodeling (syndive.org), affecting mRNAs and proteins related to synaptic organization and metabolic pathways. Strikingly, only a minority of dysregulated mRNAs/proteins were shared across excitatory and inhibitory synapses - the substantial majority were uniquely regulated at one subtype. Indeed, FMRP loss often resulted in opposing protein changes in each synapse type. Changes in mRNA or protein abundance were also not well coordinated, consistent with substantial post-transcriptional regulation, including changes to the translational and ubiquitin-dependent protein degradation machinery. For example, our data suggest a disturbed, cell type-distinct coordination of protein degradation via CAND1 as one key consequence of FMRP loss. Furthermore, we observed differences in male (Fmr1-/y) and female (Fmr1-/+) transcriptomes, where, for example, FMRP dosage was coupled to reciprocal regulation of the NDD-risk gene Trpc4 in both synapse types.

neuroscience↗

Direct disassembly of alpha-syn preformed fibrils into native alpha-syn monomers by an all-D-peptide

Parkinsons disease (PD) is the most common neurodegenerative movement disorder worldwide. One of its central features is the neurodegeneration that starts in the substantia nigra and progressively tends to involve other brain regions. -Synuclein (-syn) and its aggregation during pathogenesis have been drawn into the center of attention, where especially soluble oligomeric and fibrillar structures are thought to play a key role in cell-to-cell transmission and induction of toxic effects. Here, we report the development of all-D-enantiomeric peptide ligands that bind monomeric -syn with high affinity, thereby stabilizing the physiological intrinsically disordered structure and preventing initiation of aggregation, and more important, disassembling already existing aggregates. This "anti prionic" mode of action (MoA) has the advantage over other MoAs that it eliminates the particles responsible for disease propagation directly and independently of the immune system, thereby restoring the physiological monomer. Based on mirror image phage display on the D-enantiomeric full-length -syn target, we identified SVD-1 and SVD-1a by next generation sequencing, Thioflavin-T screens and rational design. The compounds were analyzed with regard to their anti-aggregation potential and both compounds showed aggregation delaying as well as seed capacity reducing effects in de novo and seeded environments, respectively. High affinity towards the monomeric -syn, in the low nano- to picomolar KD range was identified by surface plasmon resonance (SPR). SVD-1a reduced toxic effects as well as intracellular seeding capacity of -syn pre-fromed fibrils (PFF) in cell culture. SVD-1a disassembled -syn PFF into monomers as identified by atomic force microscopy (AFM), time dependent dynamic light scattering (DLS) and size exclusion chromatography (SEC) analysis. The present work provides promising results on the development of lead compounds with this anti-prionic mode of action for treatment of Parkinsons disease and other synucleinopathies.

neuroscience↗